摘要
目的观察重组人白细胞介素11联合自体血小板输注治疗急性白血病化学治疗(简称化疗)相关性血小板减少的临床效果。方法选取2012年6月至2013年12月住院治疗的急性白血病化疗相关性血小板减少患者40例作为观察组,采用重组人白细胞介素11联用自体血小板输注治疗,选取同期仅采用血小板输入的40例患者作为对照组,观察两组患者血小板计数变化范围、血小板恢复时间、临床疗效。结果观察组血小板计数变化范围显著高于对照组(t=5.82,P<0.05);观察组血小板计数恢复到>50×109/L和≥100×109/L时间明显低于对照组(P<0.05);观察组总不良反应发生率为17.50%,对照组总不良反应发生率为20.00%,差异无统计学意义(χ2=0.56,P>0.05)。结论重组人白细胞介素11联用自体血小板输注治疗急性白血病化疗相关性血小板减少有较好的临床疗效,安全可靠,可临床推广。
Objective ：To investigate the clinical effect of recombinant human interleukin-11 （ IL-11 ） combined with autologous platelet transfusion in the treatment of acute leukemia chemotherapy related thrombocytopenia. Methods 40 cases of acute leukemia chemothera-py related thrombocytopeni in our hospital from June 2012 to December 2013 were treated with recombinant human IL-11 combined with autologous platelet transfusion. Contemporaneous 40 cases of platelet transfusion were selected as the control group. The changes of the platelet count and platelet recovery time were observed in the two groups. The, clinical effects were compared between the two groups. Results The variation range of platelet count in the observation group was significantly higher than that in the control group, the difference was statistically significant different （ t=5. 82, P 〈 0. 05 ）; the time of platelet count returning to 〉50 × 109/L and ≥100 × 109/L in the observation group was significantly lower than that in the control group, the difference was statistically significant different （ P 〈 0. 05 ）;the occurrence rate of total adverse reactions was 17. 50% in the observation group and 20. 00% in the control group, the difference had no statistical significance （χ^2=0. 56, P 〉 0. 05 ） . Conclusion Recombinant human IL-11 combined with au-tologous platelet transfusion has better clinical effect in treatment of acute leukemia chemotherapy related thrombocytopenia, is safe and reliable, and can be widely popularized in clinic.
出处
《中国药业》
CAS
2015年第9期119-121,共3页
China Pharmaceuticals
